In order to promote the accelerated development of biomedicine and related industries, the following measures are formulated in light of the actual situation of Kunming Economic and Technological Development Zone (Kunming Pilot Free Trade Zone). Focus on supporting the development of higher value-added biotechnology, generic drugs, industrial hemp, stem cells, modern Chinese medicine, green food and other industries, as well as offshore outsourcing of services and technical services and other supporting industries.
I. Supporting the Development of Industrial Agglomeration
(1) Enterprises Entering the District
(1) Enterprises Entering the District
(2) Enterprises Entering the District
I. align: left;">For projects in line with the unit output, investment intensity, tax intensity, from the acquisition of land in accordance with the agreement on the completion of the time to put into production, three consecutive years in accordance with the formation of the economic contribution of 100% will be rewarded, the fourth to six years in accordance with the formation of the economic contribution of 60% will be rewarded. Enterprises that do not conform to the nature of the industrial land and do not carry out industrial production will not be supported. [This policy is organized and implemented by the Investment Promotion and Cooperation Bureau]
(2) Scale development of enterprises
First upgrading of industrial enterprises into a full year and maintain positive growth in output value, to give a one-time incentive of 300,000 yuan for each enterprise. [This policy is organized and implemented by the Bureau of Industry and Science and Technology]
(C) backbone enterprise development and growth
On the previous year's main business income for the first time exceeded five billion, two billion, one billion, five hundred million, one hundred million yuan of enterprises, respectively will be given a one-time capital reward of 5 million yuan, 2 million yuan, 1.5 million yuan, 1 million yuan and 200,000 yuan, and will be implemented to make up for the difference in the promotion grade. [This policy is organized and implemented by the Bureau of Industry and Science and Technology]
(4) Purchase and rental subsidies
Enterprises purchasing production and business premises can be given a one-time subsidy of up to 1,000 yuan/square meter after the commissioning of the project; the rental of production and business premises can be given a one-time subsidy of up to 1,000 yuan/square meter from the time of the enterprise's commissioning. Production and business premises, since the year of registration and payment of taxes, upon application can be given to the enterprise 1 year landing transition period, according to 30 yuan / square meter / month, to give a maximum of 1,000 square meters of rental subsidies. For the annual formation of economic contribution of more than 50,000 yuan, according to the actual area of the enterprise rented production and business premises, rent and actual investment, up to 30 yuan / square meter / month rental subsidies, rental subsidies for three consecutive years, not more than the annual formation of the enterprise's economic contribution; the fourth to fifth years depending on the production and operation of the enterprise to give half of the rental subsidies, not more than 50% of the annual economic contribution of the enterprise formation. [This policy is organized and implemented by the Bureau of Industry and Technology]
(E) offshore service outsourcing industry development
Offshore service outsourcing industry development
for the region's biotechnology offshore services for foreign institutions to provide biotechnology offshore services for bio-enterprises, the previous year's technology offshore service revenue of 10% of the total reward, a single year of technology offshore service income 10% of the total amount of the previous year's technology offshore service revenue will be rewarded, with a cap of 1 million yuan per year for a single enterprise and the same enterprise enjoying the policy for a period of no more than three years. [This policy is organized and implemented by the Bureau of Industry and Science and Technology]
(F) Specialized incubators and crowdsource space construction
Guide colleges and universities, scientific research institutes and R & D capability of enterprises around the biomedical professional industry incubators, the newly recognized national, scientific research institutes and R & D capacity of enterprises. The newly recognized national, provincial and municipal biomedical industry incubators will be given a one-time award of 1.5 million yuan, 800,000 yuan and 500,000 yuan respectively; and the newly recognized national, provincial and municipal biomedical crowdsourcing spaces will be given a one-time award of 500,000 yuan, 200,000 yuan and 100,000 yuan respectively. [This policy is organized and implemented by the Bureau of Industry and Science and Technology]
II. Support for the industrialization of new products
(VII) Innovative drug research and development
Support for enterprises or research units to obtain clinical approvals for drugs (including vaccines, blood products) or clinical filing, as well as the completion of domestic and international phase I, II, III clinical research, according to 20% of the R & D investment, respectively, the maximum 3 million yuan, 3 million yuan, 5 million yuan, 8 million yuan support. The amount of support will be adjusted according to the category of new drugs. For highly innovative Class I chemical drugs, Class I biological products (including vaccines and blood products), Class I traditional Chinese medicines and natural medicines, the proportion of support for R&D expenses will be increased to 40%, and the maximum standard of support will be as follows: according to 40% of the actual R&D expenses invested to be supported, and a maximum of 4 million RMB will be given to those who have obtained clinical approvals; and for those who have completed the Phase I, Phase II, and Phase III clinical trials, the maximum amount will be 5 million RMB, 10 million RMB, and 15 million RMB, and the maximum amount for a single drug will be 3 million RMB, 3 million RMB, 5 million RMB, and 8 million RMB, 10 million and 15 million yuan respectively for the completion of phase I, II and III clinical trials, with a maximum annual support of 50 million yuan for a single enterprise. Focus on supporting the research and development of Yunnan Taoist Chinese medicines (natural medicines) based on the "Ten Major Yunnan Medicines" such as Panax notoginseng, Calendula officinalis, Tianma, Chonglou, etc., and the innovative and improved new medicines of Chinese medicines (natural medicines) developed by using Yunnan Taoist Chinese medicines (natural medicines) as the main ingredient shall be rewarded with an increase of 10% according to the inputs in R&D stage on the basis of the aforementioned incentives of the present article. shall be rewarded. [This policy is organized and implemented by the Market Supervision Branch]
(H) generic drugs identified evaluation
The first three domestic varieties of the same species through the consistency of quality and efficacy evaluation of generic drugs (different specifications are considered a variety) [This policy is organized and implemented by the Market Supervision Bureau]
(IX) Traditional Chinese Medicine and Specialty Food Industry Development
For those who have obtained the approval of registration for the classical Chinese medicine prescription preparation, each item will be given a maximum of 1 million yuan of support. The maximum amount of support will be 1 million yuan for each item. Newly approved national standards for Chinese medicine granule varieties, each support 500,000 yuan; in the National Pharmacopoeia Committee of the new completion of the record of the provincial Chinese medicine granule standards, each variety of support for 30,000 yuan, each enterprise up to 2 million yuan per year support. For newly approved preparations for medical institutions, the record of medical institutions applying traditional techniques to formulate Chinese medicine preparations, each variety of 50% of the R & D investment to give a maximum of 300,000 yuan of support. For those who have obtained the certificate of registration of food formulas for special medical purposes, each item will be given a maximum support of 1 million yuan, and a single enterprise will be given a maximum support of 3 million yuan per year. [This policy is organized and implemented by the Market Supervision Branch]
(10) medical device research and development
The first time to obtain the certificate of registration of a medical device to land production in the region, to give the third class of medical devices 200,000 yuan for each certificate of registration, Class II medical devices each registration certificate of 100,000 yuan of incentives; for the first time in the country to get the registration certificate and in the region to land production of innovative medical devices with independent intellectual property rights, and put into production in the region, to give the Class III registration certificate of 3 million yuan each, Class II registration certificate (excluding Class II diagnostic reagents and equipment parts) each of 1 million yuan of incentives. [This policy is organized and implemented by the Market Supervision Branch]
(XI) health product development
The characteristics of health products that have received health food approval number (National Food and Health Number or record number), special use cosmetics approval number products, put into production and listed for sale for 1 year, single variety of the previous year's sales revenue reached more than 1 million yuan, according to each product 200,000 yuan to give a one-time incentive, a single enterprise does not exceed 600,000 yuan. [This policy is organized and implemented by the Market Supervision Branch]
(xii) Support for the commissioning of the production of the products of the listed drug license holder (MAH) and medical device registrant
The commissioning of the production of the products of the listed drug license holder or medical device registrant in the region is also supported by the market supervision branch. Medical device registration holder, entrusted to the region's biopharmaceutical enterprises to produce its holdings of products, and sales tax settlement in the region, according to the actual transaction of the species of 5% of the contract amount of the one-time incentives to the holder of the region and the entrusted party were given up to 5 million yuan one-time incentives, the maximum support for a single enterprise 10 million yuan per year.
Biopharmaceutical companies in the region in accordance with the drug marketing license holder system or medical device registrant system to undertake the production of enterprises (commissioned by the two sides need to be no investment in the case of the relationship), in accordance with a single variety of acceptance of commissioned production contracts each year 10% of the actual transaction costs to give the jurisdiction of the trustee of a one-time incentive. Each variety of incentives for a period of time not exceeding 3 years, the cumulative maximum of 1 million yuan, a single entrusted enterprise to support up to 2 million yuan per year.
The region's pharmaceutical or medical device manufacturers, the transfer of mature products landed in the region's production and sales settlement, the formation of the annual economic contribution of 500,000-3 million yuan (including) to give 25% support; the formation of the economic contribution of 3 million- 5 million yuan (inclusive) will be given 35% support; the formation of economic contribution of 5 million-10 million yuan (inclusive) will be given 45% support; the formation of economic contribution of 10 million-20 million yuan (inclusive) will be given 55% support; the formation of economic contribution of 20 million-30 million yuan (inclusive) will be 65% support will be given; 75% support will be given for the formation of economic contribution of 30-40 million yuan (inclusive); for the formation of economic contribution of more than 40 million yuan, the support ratio will be increased by 1% for every additional 1 million yuan, up to a maximum of 85%. For newly established pharmaceutical or medical device manufacturing enterprises in the region, the transfer of mature products to land in the region for production and sales settlement, the incentive ratio will be increased by 10% on the basis of this policy, with a maximum of 85%. The period is 3 years. This paragraph of the support policy shall be subtracted from the amount of incentives of the first two paragraphs of the same article. [This policy is responsible for the organization and implementation of the Market Supervision Branch]
(xiii) support the layout and construction of third-party testing services for drugs and medical devices in the opening area of the layout and construction of GMP common laboratories
Built by public welfare class of research institutes Platform, to take "a matter of discussion" system to give support; by the market-oriented investment and operation of the construction of the platform, according to the total project investment or new testing equipment to give support to the actual investment of 30% of the total amount of support, the maximum of 20 million yuan.
The annual revenue of the domestic service outsourcing business of more than 5 million yuan, and the annual increase of more than 35% of the enterprises, a reward of 100,000 yuan; the annual revenue of the foreign service outsourcing business of more than 500,000 U.S. dollars, and the annual increase of more than 35% of the enterprises, a reward of 100,000 yuan. ">For the first time through the U.S. FDA or the European Union CE and other certifications, and to achieve annual sales of more than 5 million yuan of products, to give 1 million yuan of one-time incentives, a single enterprise a year to obtain incentives up to 3 million yuan. [This policy is organized and implemented by the Market Supervision Branch]
(xv) enterprise qualification certification
To obtain the national drug non-clinical research quality management standard (GLP) certification of enterprises (institutions), to give a maximum of 1.5 million yuan reward; to obtain the national drug clinical trial quality management standard (GCP) filing institutions, to give a maximum of 2 million yuan reward; for the institutions that have completed the GCP filing, each new GCP filing of the specialty, to give a reward of 200,000 yuan, the cumulative total of rewards for each unit of up to 2 million yuan. [This policy is organized and implemented by the Market Supervision Branch]
(xvi) support for Chinese herbal medicine standards, Chinese medicine concoction specification revision
Chinese herbal medicine standards, Chinese medicine concoction specification for the revision of the system, and new public Published a total of 20 or more, in accordance with the standard specification for each variety of 100,000 yuan, to give the research unit up to 5 million yuan of support. Chinese herbal medicines, Chinese medicine tablets for standard specification research, is the new national standards contained in the standard specification for each variety of a one-time 1 million yuan to support the research unit; since 2021 the standard is the international mainstream pharmacopoeia or the International Organization for Standardization (ISO) adopted, each variety of 2 million yuan to support the research unit. [This policy is responsible for the organization and implementation of the market supervision branch]
This measure is responsible for the interpretation of the industry and science and technology departments and take the lead in organizing the implementation.
